睿知中国疾病研究地图
候选清单0

上海同济大学

上海市第十人民医院

Shanghai Tenth People's Hospital

在本站收录的 53 种疾病中,这家医院列在其中 12 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

上海市第十人民医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma3 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma27 篇牵头论文
  3. 胃癌Stomach cancer21 篇牵头论文
  4. 肝母细胞瘤Hepatoblastoma3 篇牵头论文
  5. 脊索瘤Chordoma0 篇牵头论文
  6. 骨肉瘤Osteosarcoma20 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  8. 神经母细胞瘤Neuroblastoma2 篇牵头论文
  9. 尤文肉瘤Ewing sarcoma0 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma5 篇牵头论文
  11. 大动脉炎Takayasu arteritis2 篇牵头论文
  12. 特发性肺纤维化Idiopathic pulmonary fibrosis2 篇牵头论文

未列出的收录疾病:鼻咽癌、视网膜母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

上海有 18 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题新辅助与综合治疗放疗早期发现与内镜
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 27 篇,占 0.2%。

牵头论文
27
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 7720222023: 7720232024: 6620242025: 332025

上海有 15 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物乙肝与肝硬化
论文中的科室消化/肝病科病理/检验科普外/肝胆胰外科

这些论文过半是实验室或动物研究。

牵头的论文27
  1. USP21 stabilizes immune checkpoint of CD276 and serves as an immunological and tumor prognostic biomarker.2025Biochemical and biophysical research communications
  2. Benefits of entecavir therapy in HBV-related hepatocellular carcinoma patients with compensated cirrhosis after hepatectomy: A ten-year retrospective cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  3. Liver ischemia-reperfusion promotes tumor metastasis via neutrophil-endothelial interactions: targeting ICAM1 to prevent metastatic recurrence.2025Journal of translational medicine免费全文
  4. TRIM65/NF2/YAP1 Signaling Coordinately Orchestrates Metabolic and Immune Advantages in Hepatocellular Carcinoma.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  5. Investigating the diagnostic and prognostic significance of genes related to fatty acid metabolism in hepatocellular carcinoma.2024BMC gastroenterology免费全文
  6. TRIM47-CDO1 axis dictates hepatocellular carcinoma progression by modulating ferroptotic cell death through the ubiquitin‒proteasome system.2024Free radical biology & medicine
  7. Exploring the Role of DNA Methylation Located in Cuproptosis-Related Genes: Implications for Prognosis and Immune Landscape in Hepatocellular Carcinoma.2024Frontiers in bioscience (Landmark edition)
  8. ZNT1 and Zn 2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor.2024Hepatology (Baltimore, Md.)
  9. Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway.2024Journal of cellular and molecular medicine免费全文
  10. Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation.2023BMC cancer免费全文
  11. Mechanism Research and Application for Ginsenosides in the Treatment of Hepatocellular Carcinoma.2023BioMed research international免费全文
  12. Harnessing function of EMT in hepatocellular carcinoma: From biological view to nanotechnological standpoint.2023Environmental research
  13. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.2023Journal of experimental & clinical cancer research : CR免费全文
  14. Protein kinases: The key contributors in pathogenesis and treatment of nonalcoholic fatty liver disease-derived hepatocellular carcinoma.2023Metabolism: clinical and experimental
  15. A systems biology-based approach to screen key splicing factors in hepatocellular carcinoma.2023Molecular carcinogenesis
  16. Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma.2023World journal of surgical oncology免费全文
  17. The therapeutic potential of exosomes derived from different cell sources in liver diseases.2022American journal of physiology. Gastrointestinal and liver physiology免费全文
  18. Circ_0000854 regulates the progression of hepatocellular carcinoma through miR-1294 /IRGQ axis.2022Clinical immunology (Orlando, Fla.)
  19. Hypomethylation of Thyroid Peroxidase as a Biomarker for Hepatocellular Carcinoma with Tumor Thrombosis.2022Current medical science
  20. The Transcription of ZIP9 Is Associated With the Macrophage Polarization and the Pathogenesis of Hepatocellular Carcinoma.2022Frontiers in immunology免费全文
  21. Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c-myc/hexokinase 2 pathway.2022Journal of cellular and molecular medicine免费全文
  22. Ligand-activated PPARδ expression promotes hepatocellular carcinoma progression by regulating the PI3K-AKT signaling pathway.2022Journal of translational medicine免费全文
  23. Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma.2022Technology in cancer research & treatment免费全文
  24. Aberrant β-catenin Activity in Hepatoid Adenocarcinoma of the Stomach.2021Current molecular medicine
  25. m6A mRNA Methylation Regulates LKB1 to Promote Autophagy of Hepatoblastoma Cells through Upregulated Phosphorylation of AMPK.2021Genes免费全文
  26. KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation.2021Journal of cellular and molecular medicine免费全文
  27. IFNγ-mediated repression of system xc- drives vulnerability to induced ferroptosis in hepatocellular carcinoma cells.2021Journal of leukocyte biology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma状态不明NCT05070156牵头方(推断)早期I期2021-10 启动
  2. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor进行中,不再招募NCT04008797研究中心I/II期2019-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 21 篇,占 0.2%。

牵头论文
21
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 6620222023: 3320232024: 101020242025: 002025

上海有 18 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
    分期
    III期
    开始
    2025-12
    登记号
    NCT07366528

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院;另有 3 家列出的医院为研究中心上海

  2. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题营养与康复手术影像与人工智能
论文中的科室消化/肝病科病理/检验科普外/肝胆胰外科肿瘤内科
牵头的论文21
  1. Modeling human gastric cancers in immunocompetent mice.2024Cancer biology & medicine免费全文
  2. Characteristics and prognostic impact of cancer cachexia defined by the Asian Working Group for Cachexia consensus in patients with curable gastric cancer.2024Clinical nutrition (Edinburgh, Scotland)
  3. Comparison between AWGC-cachexia and GLIM-malnutrition in patients with gastric cancer.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  4. Single-cell analysis uncovers high-proliferative tumour cell subtypes and their interactions in the microenvironment of gastric cancer.2024Journal of cellular and molecular medicine免费全文
  5. Epstein-Barr virus infection upregulates extracellular OLFM4 to activate YAP signaling during gastric cancer progression.2024Nature communications免费全文
  6. Muscle attenuation, not skeletal muscle index, is an independent prognostic factor for survival in gastric cancer patients with overweight and obesity.2024Nutrition (Burbank, Los Angeles County, Calif.)
  7. Differential cytokine expression in gastric tissues highlights helicobacter pylori's role in gastritis.2024Scientific reports免费全文
  8. A cofactor-induced repressive type of transcription factor condensation can be induced by synthetic peptides to suppress tumorigenesis.2024The EMBO journal免费全文
  9. The alanyl-tRNA synthetase AARS1 moonlights as a lactyltransferase to promote YAP signaling in gastric cancer.2024The Journal of clinical investigation免费全文
  10. Metabolic and immune-related gene signatures: Predictive stratification and prognostic implications in gastric cancer.2024The journal of gene medicine
  11. The Hippo signaling pathway in gastric cancer.2023Acta biochimica et biophysica Sinica免费全文
  12. Comparison of laparoscopic and open radical gastrectomy for gastric cancer patients with GLIM-defined malnutrition.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  13. METTL3-mediated m6A modification of lncRNA SNHG3 accelerates gastric cancer progression by modulating miR-186-5p/cyclinD2 axis.2023International journal of immunopathology and pharmacology免费全文
  14. Cachexia Versus Sarcopenia in Clinical Characteristics and Prognostic Value After Radical Gastrectomy for Gastric Cancer: A Large-Scale Prospective Study.2022Annals of surgical oncology
  15. ASO Author Reflections: Comparison of Sarcopenia and Cachexia for Their Prognostic Value in Gastric Cancer Patients at Different TNM Stages After Gastrectomy.2022Annals of surgical oncology
  16. Integrated Analyses of m6A Regulator-Based Signature on Its Clinical Application and Immunogenomic Landscape in Stomach Adenocarcinoma.2022BioMed research international免费全文
  17. Impact of sarcopenia on clinical outcomes of patients with stage I gastric cancer after radical gastrectomy: A prospective cohort study.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  18. Chinese and Global Burdens of Gastrointestinal Cancers From 1990 to 2019.2022Frontiers in public health免费全文
  19. Anlotinib suppresses proliferation, migration, and immune escape of gastric cancer cells by activating the cGAS-STING/IFN-β pathway.2022Neoplasma
  20. Aberrant β-catenin Activity in Hepatoid Adenocarcinoma of the Stomach.2021Current molecular medicine
  21. Development and validation of nomograms for the prediction of low muscle mass and radiodensity in gastric cancer patients.2021The American journal of clinical nutrition
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer正在招募NCT07366528研究中心III期2025-12 启动
  2. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  3. Safety and Efficacy of NK510 to Treat Gastric Cancer状态不明NCT06098898研究中心早期I期2023-11 启动
  4. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)已终止NCT03019588研究中心III期2017-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.9%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 2220232024: 0020242025: 002025

上海有 8 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年没有牵头脊索瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 15 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. The Sellar Tumor: Metastasis or Chordoma?2018The Journal of craniofacial surgery

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 20 篇,占 0.9%。

牵头论文
20
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 3320222023: 2220232024: 4420242025: 552025

上海有 60 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文20
  1. Ion interference induced by Ca-Mn nanoplatform enhances ferroptosis and promotes immune response for osteosarcoma treatment.2026Journal of advanced research
  2. Activation of HTR2B Suppresses Osteosarcoma Progression through the STAT1-NLRP3 Inflammasome Pathway and Promotes OASL1+ Macrophage Production to Enhance Antitumor Immunity.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  3. PDGFRB promotes dedifferentiation and pulmonary metastasis through rearrangement of cytoskeleton under hypoxic microenvironment in osteosarcoma.2025Cellular signalling
  4. Thrombospondin 1 Promotes Cytoskeleton Remodeling, Dedifferentiation, and Pulmonary Metastasis through ITGA1 and ITGA6 in Osteosarcoma.2025International journal of biological sciences
  5. Butyrate derived from intratumoral microbiome facilitates pulmonary metastasis in osteosarcoma.2025Pharmacological research
  6. Advances and challenges in the treatment of osteosarcoma.2025Progress in biophysics and molecular biology
  7. Photothermal Catalytic Reduction and Bone Tissue Engineering Towards a Three-in-One Therapy Strategy for Osteosarcoma.2024Advanced materials (Deerfield Beach, Fla.)
  8. Blocking CXCR4-CARM1-YAP axis overcomes osteosarcoma doxorubicin resistance by suppressing aerobic glycolysis.2024Cancer science
  9. Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index.2024Clinical and translational medicine
  10. Real-world impact of chemotherapy on overall survival in craniomaxillofacial osteosarcoma.2024Journal of stomatology, oral and maxillofacial surgery
  11. (E)-SIS3 suppressed osteosarcoma progression via promoting cell apoptosis, arresting cell cycle, and regulating the tumor immune microenvironment.2023Drug development research
  12. Transfer of exosomal microRNAs confers doxorubicin resistance in osteosarcoma cells.2023Molecular medicine reports
  13. Photothermal-triggered immunogenic nanotherapeutics for optimizing osteosarcoma therapy by synergizing innate and adaptive immunity.2022Biomaterials
  14. LncRNA ODRUL regulates progression of osteosarcoma by regulating IL-6 via sponging miR-6874-3p.2022Experimental cell research
  15. Biomineralization-inspired synthesis of amorphous manganese phosphates for GLUT5-targeted drug-free catalytic therapy of osteosarcoma.2022Nanoscale
  16. Engineering Single-Atomic Iron-Catalyst-Integrated 3D-Printed Bioscaffolds for Osteosarcoma Destruction with Antibacterial and Bone Defect Regeneration Bioactivity.2021Advanced materials (Deerfield Beach, Fla.)
  17. LncRNA SNHG16 contributes to osteosarcoma progression by acting as a ceRNA of miR-1285-3p.2021BMC cancer
  18. Identification of 6 gene markers for survival prediction in osteosarcoma cases based on multi-omics analysis.2021Experimental biology and medicine (Maywood, N.J.)
  19. CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition.2021International journal of oncology
  20. Exploration of Immune-Related Gene Expression in Osteosarcoma and Association With Outcomes.2021JAMA network open
早期论文(2016–2020 年)28
  1. Is increased symptom interval associated with advanced stage and poorer outcome? A prospective multicenter study of 220 patients with osteosarcoma around the knee.2020Cancer epidemiology
  2. LncRNA RP11-361F15.2 promotes osteosarcoma tumorigenesis by inhibiting M2-Like polarization of tumor-associated macrophages of CPEB4.2020Cancer letters
  3. LncRNA KCNQ1OT1 sponges miR-34c-5p to promote osteosarcoma growth via ALDOA enhanced aerobic glycolysis.2020Cell death & disease
  4. microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1α/HES1 signaling axis.2020Journal of experimental & clinical cancer research : CR
  5. Tripartite Motif-Containing 46 Promotes Viability and Inhibits Apoptosis of Osteosarcoma Cells by Activating NF-B Signaling Through Ubiquitination of PPAR.2020Oncology research
  6. Treatment-Related Prognostic Factors in Managing Osteosarcoma around the Knee with Limb Salvage Surgery: A Lesson from a Long-Term Follow-Up Study.2019BioMed research international
  7. MiR-92a modulates proliferation, apoptosis, migration, and invasion of osteosarcoma cell lines by targeting Dickkopf-related protein 3.2019Bioscience reports
  8. Limb salvage for malignant bone tumours of distal tibia with dual ipsilateral vascularized autogenous fibular graft in a trapezoid-shaped array with ankle arthrodesis and preserving subtalar joint.2019Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons
  9. Targeting autophagy is a promising therapeutic strategy to overcome chemoresistance and reduce metastasis in osteosarcoma.2019International journal of oncology
  10. Fibronectin-1 modulated by the long noncoding RNA OIP5-AS1/miR-200b-3p axis contributes to doxorubicin resistance of osteosarcoma cells.2019Journal of cellular physiology
  11. Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance.2019Molecular therapy : the journal of the American Society of Gene Therapy
  12. Serine/Threonine Kinase 35, a Target Gene of STAT3, Regulates the Proliferation and Apoptosis of Osteosarcoma Cells.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  13. Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing.2018Epigenomics
  14. A novel circulating hsa_circ_0081001 act as a potential biomarker for diagnosis and prognosis of osteosarcoma.2018International journal of biological sciences
  15. Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1.2018International journal of biological sciences
  16. MicroRNA-18a inhibits cell growth and induces apoptosis in osteosarcoma by targeting MED27.2018International journal of oncology
  17. Survival, complications and functional outcomes of cemented megaprostheses for high-grade osteosarcoma around the knee.2018International orthopaedics
  18. MicroRNA-3200-5p Promotes Osteosarcoma Cell Invasion via Suppression of BRMS1.2018Molecules and cells
  19. Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2.2017Cancer letters
  20. MicroRNA-661 Enhances TRAIL or STS Induced Osteosarcoma Cell Apoptosis by Modulating the Expression of Cytochrome c1.2017Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  21. Antisense lncRNA FOXF1-AS1 Promotes Migration and Invasion of Osteosarcoma Cells Through the FOXF1/MMP-2/-9 Pathway.2017International journal of biological sciences
  22. Alternol, a natural compound, exerts an anti-tumour effect on osteosarcoma by modulating of STAT3 and ROS/MAPK signalling pathways.2017Journal of cellular and molecular medicine
  23. Shikonin promotes adriamycin‑induced apoptosis by upregulating caspase‑3 and caspase‑8 in osteosarcoma.2017Molecular medicine reports
  24. [Sensitivity of doxorubicin-resistant osteosarcoma cells to doxorubicin regulated by long non-coding RNA NR_036444].2017Zhonghua zhong liu za zhi [Chinese journal of oncology]
  25. MiR-329 suppresses osteosarcoma development by downregulating Rab10.2016FEBS letters
  26. Benzochloroporphyrin derivative photosensitizer-mediated photodynamic therapy for Ewing sarcoma.2016Journal of photochemistry and photobiology. B, Biology
  27. SOX18 knockdown suppresses the proliferation and metastasis, and induces the apoptosis of osteosarcoma cells.2016Molecular medicine reports
  28. A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 21 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

上海有 34 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 15 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Benzochloroporphyrin derivative photosensitizer-mediated photodynamic therapy for Ewing sarcoma.2016Journal of photochemistry and photobiology. B, Biology

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.3%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 2220232024: 1120242025: 002025

上海有 16 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层肾脏与骨骼并发症

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.1%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

上海有 8 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室儿科肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

上海有 34 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

上海市第十人民医院

Shanghai Tenth People's Hospital

上海

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Shanghai Tenth People's Hospital of Tongji University; Shanghai Tenth People's Hospital Affiliated to Tongji University; Tenth People's Hospital of Tongji University; Shanghai Tenth People's Hospital & Putuo District People's Hospital; Shanghai Tenth Peoples' Hospital affiliated Tongji University; Shanghai Tenth People' s Hospital; Shanghai Tenth Peoples' Hospital; Shanghai Tenth People's Hospital Tongji University

提出更正下载数据